Enhancement of radiation response of prostatic carcinoma by lonidamine

Scott D. Dudak, Armando Lopez, Norman L. Block, Balakrishna L Lokeshwar

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Potential application of Ionidamine (LND) to enhance radiation toxicity in prostate cancer was investigated using human prostate cancer cell lines and a rat tumor model (Dunning MAT LyLu). LND alone was cytotoxic with 50% inhibition concentration (IC50) between 0.5 and 0.8 mM. Preincubation with LND increased clonogenic toxicity of radiation. The sensitizer enhancement ratio was 1.8 to 2.2, depending on the cell line tested and it was consistent with inhibition of repair from potentially lethal damage. LND had limited effect in vivo on the Dunning model, consistent with its in vitro effect on the same cell line. LND did not alter the primaiy growth of the tumor. Fractionated irradiation caused a 40% decrease in tumor growth. LND injection (50 mg/kg) before fractionation did not cause any further decrease in tumor growth. Radiation dose fractionation and the combination treatment significantly reduced tumor metastasis in lungs.

Original languageEnglish (US)
Pages (from-to)3665-3672
Number of pages8
JournalAnticancer Research
Volume16
Issue number6 B
StatePublished - Dec 1 1996
Externally publishedYes

Fingerprint

Radiation
Carcinoma
Neoplasms
Cell Line
Prostatic Neoplasms
Growth
Dose Fractionation
Inhibitory Concentration 50
lonidamine
Neoplasm Metastasis
Lung
Injections
Therapeutics

Keywords

  • Adjuvant trherapy
  • Ionidamine
  • Prostate cancer
  • Radiation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Enhancement of radiation response of prostatic carcinoma by lonidamine. / Dudak, Scott D.; Lopez, Armando; Block, Norman L.; Lokeshwar, Balakrishna L.

In: Anticancer Research, Vol. 16, No. 6 B, 01.12.1996, p. 3665-3672.

Research output: Contribution to journalArticle

Dudak, SD, Lopez, A, Block, NL & Lokeshwar, BL 1996, 'Enhancement of radiation response of prostatic carcinoma by lonidamine', Anticancer Research, vol. 16, no. 6 B, pp. 3665-3672.
Dudak, Scott D. ; Lopez, Armando ; Block, Norman L. ; Lokeshwar, Balakrishna L. / Enhancement of radiation response of prostatic carcinoma by lonidamine. In: Anticancer Research. 1996 ; Vol. 16, No. 6 B. pp. 3665-3672.
@article{9d47cce41d934cd8ae8cdce0036ac703,
title = "Enhancement of radiation response of prostatic carcinoma by lonidamine",
abstract = "Potential application of Ionidamine (LND) to enhance radiation toxicity in prostate cancer was investigated using human prostate cancer cell lines and a rat tumor model (Dunning MAT LyLu). LND alone was cytotoxic with 50{\%} inhibition concentration (IC50) between 0.5 and 0.8 mM. Preincubation with LND increased clonogenic toxicity of radiation. The sensitizer enhancement ratio was 1.8 to 2.2, depending on the cell line tested and it was consistent with inhibition of repair from potentially lethal damage. LND had limited effect in vivo on the Dunning model, consistent with its in vitro effect on the same cell line. LND did not alter the primaiy growth of the tumor. Fractionated irradiation caused a 40{\%} decrease in tumor growth. LND injection (50 mg/kg) before fractionation did not cause any further decrease in tumor growth. Radiation dose fractionation and the combination treatment significantly reduced tumor metastasis in lungs.",
keywords = "Adjuvant trherapy, Ionidamine, Prostate cancer, Radiation",
author = "Dudak, {Scott D.} and Armando Lopez and Block, {Norman L.} and Lokeshwar, {Balakrishna L}",
year = "1996",
month = "12",
day = "1",
language = "English (US)",
volume = "16",
pages = "3665--3672",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 B",

}

TY - JOUR

T1 - Enhancement of radiation response of prostatic carcinoma by lonidamine

AU - Dudak, Scott D.

AU - Lopez, Armando

AU - Block, Norman L.

AU - Lokeshwar, Balakrishna L

PY - 1996/12/1

Y1 - 1996/12/1

N2 - Potential application of Ionidamine (LND) to enhance radiation toxicity in prostate cancer was investigated using human prostate cancer cell lines and a rat tumor model (Dunning MAT LyLu). LND alone was cytotoxic with 50% inhibition concentration (IC50) between 0.5 and 0.8 mM. Preincubation with LND increased clonogenic toxicity of radiation. The sensitizer enhancement ratio was 1.8 to 2.2, depending on the cell line tested and it was consistent with inhibition of repair from potentially lethal damage. LND had limited effect in vivo on the Dunning model, consistent with its in vitro effect on the same cell line. LND did not alter the primaiy growth of the tumor. Fractionated irradiation caused a 40% decrease in tumor growth. LND injection (50 mg/kg) before fractionation did not cause any further decrease in tumor growth. Radiation dose fractionation and the combination treatment significantly reduced tumor metastasis in lungs.

AB - Potential application of Ionidamine (LND) to enhance radiation toxicity in prostate cancer was investigated using human prostate cancer cell lines and a rat tumor model (Dunning MAT LyLu). LND alone was cytotoxic with 50% inhibition concentration (IC50) between 0.5 and 0.8 mM. Preincubation with LND increased clonogenic toxicity of radiation. The sensitizer enhancement ratio was 1.8 to 2.2, depending on the cell line tested and it was consistent with inhibition of repair from potentially lethal damage. LND had limited effect in vivo on the Dunning model, consistent with its in vitro effect on the same cell line. LND did not alter the primaiy growth of the tumor. Fractionated irradiation caused a 40% decrease in tumor growth. LND injection (50 mg/kg) before fractionation did not cause any further decrease in tumor growth. Radiation dose fractionation and the combination treatment significantly reduced tumor metastasis in lungs.

KW - Adjuvant trherapy

KW - Ionidamine

KW - Prostate cancer

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=0030514287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030514287&partnerID=8YFLogxK

M3 - Article

C2 - 9042239

AN - SCOPUS:0030514287

VL - 16

SP - 3665

EP - 3672

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 B

ER -